Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain

Neuroscience Letters

Volumn 470, Issue 2, 2010, Pages 91-94

  Christoph, Thomas ^a   De Vry, Jean ^a   Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Animals; Diabetic neuropathic pain; Opioids; Tapentadol

Indexed keywords

MORPHINE; MU OPIATE RECEPTOR; NORADRENALIN; TAPENTADOL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HOT PLATE TEST; HYPERALGESIA; MALE; MOUSE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; NORADRENALIN UPTAKE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, OPIOID; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HOT TEMPERATURE; HYPERALGESIA; MALE; MICE; MICE, INBRED STRAINS; MORPHINE; NEURALGIA; PAIN MEASUREMENT; PHENOLS; TREATMENT OUTCOME;

EID: 74449091483     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.12.020     Document Type: Article

References (24)

1. Baron R., Tölle T.R., Gockel U., Brosz M., and Feynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 146 (2009) 34-40
2. Codd E.E., Martinez R.P., Molino L., Rogers K.E., Stone D.J., and Tallarida R.J. Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain 134 (2008) 254-262
3. Daniels S., Casson E., Stegmann J.U., Oh C., Okamoto A., Rauschkolb C., and Upmalis D. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr. Med. Res. Opin. 25 (2009) 1551-1561
4. Daniels S.E., Upmalis D., Okamoto A., Lange C., and Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr. Med. Res. Opin. 25 (2009) 765-776
5. Dyck P.J., Dyck P.J.B., Larson T.S., O'Brien P.C., and Velosa J.A. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 23 (2000) 510-517
6. Etropolski M., Shapiro D.Y., Okamoto A., Rauschkolb C., and Haeussler J. Efficacy and safety of tapentadol ER for diabetic peripheral neuropathic pain: results of a randomized-withdrawal, double-blind, placebo-controlled phase III study. Neurology 72 11 Suppl. 3 (2009) A217-A218
7. Field M.J., McCleary S., Hughes J., and Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80 (1999) 391-398
8. Filitz J., Ihmsen H., Gunther W., Troster A., Schwilden H., Schuttler J., and Koppert W. Supra-additive effects of tramadol and acetaminophen in a human pain model. Pain 136 (2008) 262-270
9. Hale M., Upmalis D., Okamoto A., Lange C., and Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr. Med. Res. Opin. 25 (2009) 1095-1104
10. Hartrick C., Van Hove I., Stegmann J.-U., Oh C., and Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin. Ther. 31 (2009) 260-271
11. Jensen T.S., Backonja M.M., Hernandez J.S., Tesfaye S., Valensi P., and Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab. Vasc. Dis. Res. 3 (2006) 108-119
12. Kamei J., Ohhashi Y., Aoki T., Kawasima N., and Kasuya Y. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists. Brain Res. 571 (1992) 199-203
13. Kohno T., Ji R.R., Ito N., Allchorne A.J., Befort K., Karchewski L.A., and Woolf C.J. Peripheral axonal injury results in reduced μ opioid receptor pre- and post-synaptic action in the spinal cord. Pain 117 (2005) 77-87
14. Kuhad A., Bishnoi M., and Chopra K. Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J. Exp. Biol. 47 (2009) 193-197
15. Marchand F., Alloui A., Chapuy E., Hernandez A., Pelissier T., Ardid D., and Eschalier A. The antihyperalgesic effect of venlafaxine in diabetic rats does not involve the opioid system. Neurosci. Lett. 342 (2003) 105-108
16. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., and Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. 326 (1992) 1250-1256
17. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 (2002) 355-474
18. Ossipov M.H., Lopez Y., Nichols M.L., Bian D., and Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci. Lett. 199 (1995) 83-86
19. Staiger T.O., Gaster B., Sullivan M.D., and Deyo R.A. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 28 (2003) 2540-2545
20. Tzschentke T.M., Christoph T., Kögel B., Schiene K., Hennies H.-H., Englberger W., Haurand M., Jahnel U., Cremers T.I., Friderichs E., and De Vry J. (-)-(1R, 2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther. 323 (2007) 265-276
21. Tzschentke T.M., De Vry J., Terlinden R., Hennies H.H., Lange C., Strassburger W., Haurand M., Kolb J., Schneider J., Buschmann H., Finkam M., Jahnel U., and Friderichs E. Tapentadol HCl. Drugs Future 31 (2006) 1053-1061
22. Tzschentke T.M., Jahnel U., Kogel B., Christoph T., Englberger W., De V.J., Schiene K., Okamoto A., Upmalis D., Weber H., Lange C., Stegmann J.U., and Kleinert R. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 45 (2009) 483-496
23. Veves A., Backonja M., and Malik R.A. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 9 (2008) 660-674
24. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110